The former AstraZeneca and Vertex Pharmaceuticals executive bolsters the agency’s value, access, and reimbursement practice.
Tag Archive for: real world data
Through its collaboration with the Oracle Cerner LHN, Syneos Health’s objective is to improve performance throughout the entire clinical trial lifecycle, with a strong emphasis on clinical trial enrollment to help close diversity gaps in patient recruitment.
The Ffrst-of-its-kind targeting predicts which patients will become non-adherent in the next 30 days. The new offering leverages Swoop’s best-in-class machine learning and artificial intelligence.
In the ever-changing world of digital marketing, staying ahead of the curve is critical for healthcare brands looking to effectively reach Patient X. With the impending demise of third-party cookies, marketers must adapt their strategies to continue connecting with prospective patients in a relevant and impactful manner.
Real-world data (RWD) improves health care – especially patient safety. The data enhances signal detection and management to identify and evaluate potential safety concerns. While it offers many advantages over traditional data sources for pharmacovigilance, simply having data is not enough. For optimal utility, healthcare entities must use effective data management tools.
Generative AI such as Amazon’s HealthScribe transcribing patient visits may open a whole new world of real-world evidence by organizing unstructured and untapped data sources in EHRs.
Organizations continue to recognize the value of the large volumes of data they have collected and their potential for improving the quality, safety, and continuity of care. To utilize the data effectively and appropriately realize these benefits, organizations must overcome the challenges associated with transforming the data for use in healthcare.
Although the pandemic gave a boost to the drug discovery market, accelerated development in the market will be influenced by effective use of data and analytics.
Jazz Pharmaceuticals plc announced new real-world data from the BECOME (BEhavior, COgnition, and More with Epidiolex) Caregiver Survey that showed a substantial proportion of caregivers of adult and pediatric patients with Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS) prescribed Epidiolex (cannabidiol) oral solution reported improvements in patients’ seizure and non-seizure outcomes across all age groups.
Matthew W. Reynolds, Ph.D., vice president, scientific affairs, real world solutions, IQVIA, explains how RWE can provide a greater picture of a disease’s progression as well as a blueprint for future outbreaks.
